Roger D. Dansey - Nov 9, 2022 Form 4 Insider Report for Seagen Inc. (SGEN)

Role
President, Research & Development & Chief Medical Officer
Signature
/s/ Jennifer Prosba, for Roger D. Dansey
Stock symbol
SGEN
Transactions as of
Nov 9, 2022
Transactions value $
$0
Form type
4
Date filed
11/14/2022, 05:15 PM
Previous filing
Oct 19, 2022
Next filing
Dec 16, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SGEN Non-Qualified Stock Option (Right to Buy) Award $0 +275K $0.00 275K Nov 9, 2022 Common Stock 275K $137.96 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Options are subject to performance vesting in tranches tied to price targets for shares of the Issuer's common stock generally achievable on specified timelines on or before December 31, 2028 or an earlier change of control of the Issuer. Each such tranche will time-vest 1/3 on the date of performance vesting, 1/3 on the 9 month anniversary of performance vesting and 1/3 on the 18 month anniversary of performance vesting.

Remarks:

President, Research & Development & Chief Medical Officer